HALEOS LABS credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
10910984.097.798.6
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
10610682.596.294.2
0.47×0.47×0.40×0.50×0.52×
0.46×0.46×0.39×0.50×0.50×
2.44×2.44×1.87×3.14×3.43×
2.60×2.38×1.83×3.09×3.28×
4.53×4.53×3.45×1.59×2.64×
32.2%32.2%28.4%33.5%34.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HALEOSLABS₹1,429.20

HALEOS LABS LIMITED

· Pharma & Health
₹ CrorePeersALBERTDAVDVALIANTLABMEDICOMEDICAMEQZIMLABAAREYDRUGSNECLIFEANUHPHRMcap ₹432 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt98.697.784.0108.9108.9
Net Debt94.296.282.5106.5106.5
Total Debt/Equity0.520.500.400.470.47
Net Debt/Equity0.500.500.390.460.46
Total Debt/EBITDA3.433.141.872.442.44
Net Debt/EBITDA3.283.091.832.382.60
Interest Coverage (EBIT/Interest)2.641.593.454.534.53
Total Debt/Total Capital %34.3933.5428.3832.1732.17
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.